Galapagos NV (NASDAQ:GLPG) Receives $30.75 Consensus PT from Brokerages

Shares of Galapagos NV (NASDAQ:GLPG) have been assigned an average rating of “Reduce” from the nine brokerages that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell recommendation and five have given a hold recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $30.75.

GLPG has been the topic of a number of research reports. Royal Bank of Canada dropped their target price on shares of Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a report on Friday, November 1st. TD Cowen cut shares of Galapagos from a “strong-buy” rating to a “strong sell” rating in a report on Thursday, January 9th. Barclays restated an “underweight” rating on shares of Galapagos in a report on Thursday, January 23rd. Finally, Kepler Capital Markets cut shares of Galapagos from a “hold” rating to a “reduce” rating in a report on Wednesday, November 20th.

Hedge Funds Weigh In On Galapagos

Several large investors have recently modified their holdings of GLPG. GAMMA Investing LLC raised its position in Galapagos by 140.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock worth $36,000 after buying an additional 736 shares during the last quarter. R Squared Ltd purchased a new position in Galapagos in the 4th quarter worth about $26,000. American Century Companies Inc. raised its position in Galapagos by 5.9% in the 4th quarter. American Century Companies Inc. now owns 25,852 shares of the biotechnology company’s stock worth $711,000 after buying an additional 1,431 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in Galapagos by 63.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock worth $112,000 after buying an additional 1,510 shares during the last quarter. Finally, QRG Capital Management Inc. raised its position in Galapagos by 21.7% in the 4th quarter. QRG Capital Management Inc. now owns 10,455 shares of the biotechnology company’s stock worth $288,000 after buying an additional 1,866 shares during the last quarter. Hedge funds and other institutional investors own 32.46% of the company’s stock.

Galapagos Stock Performance

Shares of GLPG stock opened at $25.49 on Friday. Galapagos has a 12 month low of $22.36 and a 12 month high of $40.34. The company’s fifty day moving average price is $25.54 and its 200-day moving average price is $27.08.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.